Clinical impact of cell-free serum Epstein–Barr virus status in patients with newly diagnosed malignant lymphoma

Dong-Won BAEK; Jung-Min LEE; Juhyung KIM; Hee-Jeong CHO; Sang-Kyun SOHN; Ji-Yeon HAM; Soon-Hee CHANG; Joon-Ho MOON; Deok-Hwan YANG.
Blood Research ; : 65-71, 2021.
Artículo en Inglés | WPRIM | ID: wpr-897365

Documentos relacionados

  1. Clinical impact of cell-free serum Epstein–Barr virus status in patients with newly diagnosed malignant lymphoma
  2. Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma.
  3. Epstein-Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018.
  4. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
  5. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
  6. [The diagnostic value of flow cytometry in patients with lymphoma associated hemophagocytic syndrome].